The 5th USPTO patent for Compass Pathways covers methods of treating depression with crystalline psilocybin.
The 5th USPTO patent for Compass Pathways covers methods of treating depression with crystalline psilocybin.
Digital therapeutics is the key to the rapid commercialization of psychedelic medicine. MINDCURE's iSTRYM digital therapeutics platform is the first-mover in the industry.
Psychedelic medicine is both extremely efficacious and highly cost-effective. It is also an absolute necessity to RESCUE the economy.
Novamind announces an LOI to add two Arizona mental health clinics to its treatment network.
Cybin Inc reports its fiscal Q2 results for 2021. Advanced several drug development candidates and received a Schedule I manufacturing license. Cash and equivalents of CAD$75.2 million as of September 30, 2021.
MindMed announces its Q3 2021 results. Continued progress on R&D and pipeline development. Cash and equivalents of $178.6 million.
atai Life Sciences reports its Q3 2021 financial results. Continued progress across 11 therapeutic research programs. Cash and equivalents of $430.3 million as of September 30, 2021.
Levitte Labs announce an LOI for the acquisition of 3 more pharmacies specializing in addiction.
Numinus' Montreal and Vancouver clinics will be host for an extension of the MAPS Phase III clinical trial on MDMA-assisted therapy for PTSD.
Novamind reports that four health insurers are now covering its ketamine treatment for Treatment-Resistant Depression.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now